Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Glioma 2Brain Neoplasms 2Waldenstrom Macroglobulinemia 1Unspecified Adult Solid Tumor, Protocol Specific 1Solid Tumors 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Glioblastoma 1Fallopian Tube Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1Astrocytoma 1

Interventions

Sunitinib 4Cyclophosphamide 4Capecitabine 4Bevacizumab 4pazopanib 3Topotecan 3Paclitaxel 3Docetaxel 3Carboplatin 3temsirolimus 2liposomal doxorubicin 2fludarabine 2Sorafenib 2Panobinostat 2NVP-BKM120 2Lapatinib 2Irinotecan 2Immune Checkpoint Inhibitors 2Gemcitabine 2Everolimus 2Erlotinib Hydrochloride 2Doxorubicin 2Bortezomib 2vadimezan 1spartalizumab 1somatostatin receptor 2 1selinexor 1selicrelumab 1perifosine 1pegylated granulocyte colony-stimulating factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Solid Tumors × perifosine × Clear all
NCT00776867 2017-08-01

Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
38 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡